Skip to main content
. 2012 Sep 6;107(8):1249–1256. doi: 10.1038/bjc.2012.389

Table 3. Prevalence and odds ratio (OR) associated with adherence for each of the methods used.

  Physician report
Telephone questionnaire
Pharmacy administrative database
  n (%) ORa n (%) ORb n (%) ORc
Age at diagnosis
 ⩽49 183 (90.7) 1 138 (84.8) 1 176 (64.8) 1
 50–74 419 (95.5) 1.71 (0.72–4.06) 330 (94.2) 2.75 (1.41–5.36)a 409 (79.0) 1.67 (1.03–2.70)a
 ⩾75 90 (94.4) 2.56 (0.68–9.63) 38 (86.8) 1.07 (0.37–3.12) 88 (67.0) 1.60 (0.76–3.36)
P-value 0.075   0.003a   0.001a  
 
Stage
 I 321 (93.5) 1 249 (92.8) 1 314 (74.2) 1
 IIA 200 (95.0) 0.89 (0.36–2.19) 142 (90.1) 0.81 (0.38–1.71) 192 (78.1) 1.09 (0.67–1.77)
 IIB 93 (93.5) 0.72 (0.25–2.1) 64 (87.5) 0.63 (0.25–1.56) 91 (64.8) 0.57 (0.32–1)a
 IIIA 42 (95.2) 1.2 (0.24–5.96) 30 (90.0) 0.62 (0.16–2.33) 40 (77.5) 1.09 (0.46–2.58)
 TNMx 36 (94.4) 1.01 (0.2–5.09) 21 (90.5) 0.87 (0.17–4.50) 36 (63.9) 0.67 (0.29–1.58)
P-value 0.953   0.718   0.101  
 
Surgical treatment
 Yes 681 (94.1) 1 505 (91.1) 1 663 (74.2) 1
 No 11 (90.9) 1.63 (0.16–17.14) 1 (100.0) 10 (40.0) 2.14 (0.51–8.98)
P-value 0.654   0.911   0.015a  
 
Type of surgical treatment
 Conservative breast surgery 536 (93.7) 1 394 (91.4) 1 523 (74.8) 1
 Radical breast surgery 145 (95.9) 1.34 (0.51–3.5) 111 (90.1) 1.09 (0.50–2.34) 140 (72.1) 1.47 (0.80–2.68)
P-value 0.426   0.706   0.516  
 
Radiotherapy
 No 132 (91.7) 1 85 (91.8) 1 128 (62.5) 1
 Yes 560 (94.6) 1.8 (0.8–4.05) 421 (91.0) 0.65 (0.27–1.57) 545 (76.3) 1.48 (0.93–2.36)
P-value 0.193   0.815   0.001a  
 
Neoadjuvant chemotherapy
 No 598 (94.1) 1 445 (90.8) 1 582 (74.6) 1
 Yes 94 (93.6) 0.79 (0.28–2.2) 61 (93.4) 1.79 (0.59–5.44) 91 (68.1) 0.57 (0.33–1)
P-value 0.840   0.494   0.195  
 
Adjuvant chemotherapy
 No 331 (92.1) 1 231 (91.8) 1 322 (68.6) 1
 Yes 361 (95.8) 2.14 (1.01–4.53)a 275 (90.5) 0.89 (0.44–1.81) 351 (78.3) 1.60 (1.05–2.43)a
P-value 0.039a   0.628   0.004a  
 
Endocrine therapy
 Tamoxifen 200 (89.0) 1 136 (89.7) 1 193 (60.6) 1
 Inhibitors 206 (94.7) 2.06 (0.82–5.17) 142 (90.9) 0.53 (0.19–1.48) 201 (78.1) 2 (1.18–3.38)a
 Tamoxifen + inhibitors 243 (98.4) 6.28 (1.93–20.45)a 197 (92.9) 0.65 (0.26–1.64) 238 (84.5) 2.27 (1.34–3.84)a
 Others 43 (94.1) 1.24 (0.38–4.03) 31 (87.1) 0.52 (0.15–1.84) 41 (51.2) 0.55 (0.27–1.13)
P-value <0.001a   0.630   <0.001a  
 
Side effects b
 No 309 (92.2) 1 209 (90.9) 1 298 (69.5) 1
 Yes 383 (95.6) 1.81 (0.81–4.02) 297 (91.2) 1.06 (0.49–2.28) 375 (77.1) 1.25 (0.81–1.93)
P-value 0.048a   0.508   0.016a  

Abbreviations: ORa=adjusted for centre, age at diagnosis, adjuvant chemotherapy, adverse effects and endocrine therapy; ORb=adjusted for centre, age at diagnosis; ORc=adjusted for centre, age at diagnosis, adjuvant chemotherapy, radiotherapy, side effects and endocrine therapy.

n (%)=number of cases (% adherence); P-value: χ2-test.

a

Statistical significance, P<0.05.

b

Adverse effects of physician report.